November 2017 - Cancer Currents Blog
- Experimental Ovarian Cancer Vaccine Shows Promise in Mice
The vaccine targets a protein found at elevated levels in about 90% of the most common type of ovarian cancer. If validated in human studies, researchers believe the vaccine may be particularly useful for women who carry BRCA1 and BRCA2 gene mutations.
- Many Ovarian Cancers May Start in Fallopian Tubes, Study Finds
A new study provides more evidence that the most common form of ovarian cancer may originate in the fallopian tubes, and that there is a window of nearly 7 years between development of fallopian tube lesions and the start of ovarian cancer.
- Alternate Driver of Treatment-Resistant Prostate Cancer Identified
Researchers have identified an emerging subtype of metastatic prostate cancer that is resistant to therapies that block hormones that fuel the disease.
- Study Identifies Potential Drug Combination for Ewing Sarcoma
From experiments in cells and mice, researchers have identified a two-drug combination that kills more Ewing sarcoma cells than either drug on its own. The study findings could help inform future clinical trials.
- Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer
Research studies show tests that analyze tumor DNA in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment response.
- Study Tracks the Evolution of Treatment Resistance in Metastatic Breast Cancer
A new study suggests that the cells in treatment-resistant tumors in women with metastatic breast cancer share important characteristics that could potentially make tumors vulnerable to therapies that otherwise might not have been considered.
- Levels of Immune Cells within Ovarian Tumors Linked to Survival for Some Patients
A large international study suggests that the presence of certain immune cells within the tumors of some patients with ovarian cancer are associated with improved survival.
- Assuming the Role of NCI Director: Working to Accelerate Progress
Norman Sharpless, M.D., discusses his appointment as the director of the National Cancer Institute and his plans for continuing NCI’s long tradition of research excellence and commitment to improving people’s lives.